Table 2 Self-reported uptake of praziquantel at baseline and follow-up surveys
School (no) | Baseline (N = 1,010) | Follow-up (N = 1,020) | P value | ||||
|---|---|---|---|---|---|---|---|
| Â | n | Uptake | % uptake (95% CI) | n | Uptake | % uptake (95% CI) | Â |
1 | 70 | 12 | 17.1 (2.08–48.4) | 75 | 44 | 58.7 (43.2–73.7) | 0.011 |
2 | 61 | 16 | 26.2 (7.27–52.3) | 70 | 39 | 55.7 (39.6–72.2) | 0.047 |
3 | 75 | 19 | 25.3 (9.14–51.2) | 70 | 44 | 62.9 (47.8–77.6) | 0.006 |
4 | 55 | 38 | 69.0 (51.3–82.4) | 71 | 28 | 39.4 (21.5–59.4) | 0.017 |
5 | 31 | 20 | 64.5 (40.7–84.6) | 73 | 30 | 41.4 (22.6–59.4) | 0.109 |
6 | 104 | 26 | 25.0 (11.5–47.8) | 100 | 45 | 45.0 (29.6–60.0) | 0.093 |
7 | 107 | 25 | 23.4 (9.35–45.1) | 100 | 53 | 53.0 (38.6–66.7) | 0.014 |
8 | 107 | 12 | 11.2 (0.21–38.4) | 92 | 56 | 60.9 (46.7–73.5) | 0.002 |
9 | 82 | 48 | 58.5 (43.2–72.4) | 71 | 42 | 59.2 (43.2–74.4) | 0.946 |
10 | 104 | 17 | 16.3 (3.70–43.4) | 101 | 55 | 54.5 (40.5–68.0) | 0.006 |
11 | 110 | 28 | 25.5 (10.6–44.9) | 98 | 13 | 13.3 (1.90–45.4) | 0.377 |
12 | 104 | 24 | 23.1 (9.77–46.7) | 99 | 50 | 50.5 (35.5–64.5) | 0.025 |
Total | 1,010 | 285 | 28.2 (22.9–33.6) | 1,020 | 499 | 48.9 (44.4–53.4) | <0.001 |